Eppendorf

Liquid Handling System Market worth $5.8 billion | MarketsandMarkets

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Science, Gilson, Beckman Coulter, Agilent Technologies, Workflow, Thermo Fisher Scientific, PerkinElmer, Software, Oxygen, ROW, Danaher Corporation, Mindful Scientific Inc., Research, Row, Application, Proteomics, Growth, Genomics, Drug discovery, Automation, Medical device, Instrumentation, Pipette, Eppendorf, Liquid, Roe (disambiguation)

The automated liquid handling systems segment holds a major share of the global Liquid handling system market, By type, in 2021

Key Points: 
  • The automated liquid handling systems segment holds a major share of the global Liquid handling system market, By type, in 2021
    By type, the global Liquid handling system market is broadly segmented into electronic systems, automated systems, and manual systems.
  • In 2021, the Automated liquid handling systems segment dominated Liquid handling system market.
  • The drug discovery segment accounted for the largest share of the Liquid handling system devices market, by Application, in 2021
    By application, the global Liquid handling system are classified into drug discovery, clinical diagnostics, genomics, proteomics, and other applications.
  • Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=192124302
    Liquid Handling System Market Dynamics:
    The major players in the Liquid Handling System are the liquid handling system market is highly consolidated and is dominated by various players.

The Engine Opens New Headquarters in Cambridge: 155,000 Square Foot Building with Bio and Chem Labs, Industrial Workshops, and Office and Event Space Will Bring Together the Tough Tech Ecosystem

Retrieved on: 
Thursday, September 29, 2022
Technology, Engineering, Architecture, Manufacturing, Finance, Asset Management, Professional Services, Construction & Property, Machine Tools, Metalworking & Metallurgy, Environment, Research, Hardware, Science, Climate Change, Partner, Triumvirate, Health, Eppendorf, Engineering, ISEE, The Engine, MIT, Industry, Climate change, Foundation, Cambridge Consultants, Desktop Metal, CEO, Hilti, Technology, Biology, Goal, Solution, Science, Ecosystem, Gensler, AET, Thermo Fisher Scientific, Central Square Theater, Polaroid, View, Renewable energy, Engine, Tech, Main

The Engine , built by MIT, today announced the opening of The Engine at 750 Main, its new headquarters in Cambridge.

Key Points: 
  • The Engine , built by MIT, today announced the opening of The Engine at 750 Main, its new headquarters in Cambridge.
  • The Engine invests in Tough Techtransformative technology that solves the worlds most important challengesthrough a venture fund, network, and spaces and infrastructure.
  • Tough Tech is deeply cross-functional, combining fields like biology with material science or industrial design with quantum computing.
  • Located between Cambridges Kendall and Central Squares, The Engine at 750 Main is purpose-built to foster the Tough Tech ecosystem.

Streamlined Microbiome Sequencing through Automation, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, September 6, 2022
Automation, NGS, Library, Food, Research, Eppendorf, Industry, Environment, Health, Therapy, Mobile phone, Antibiotics

TORONTO, September 06, 2022 /PRNewswire-PRWeb/ -- Next-generation sequencing (NGS) is revolutionizing the advancements in microbiological sciences and our understanding of the impact of microbial communities on the environment and human health. Consequently, microbiome research offers the potential to transform the healthcare landscape and provide novel diagnostics and therapeutics.

Key Points: 
  • In this free webinar, learn about the common challenges in microbiome research and how automating sample preparation can assist microbiome sequencing and bring reliable and trusted results.
  • The speaker will also discuss some of the common challenges in microbiome research and how automating sample preparation can assist microbiome sequencing and bring reliable and trusted results.
  • Join this webinar to learn more about streamlining microbiome sequencing with laboratory liquid handling solutions.
  • For more information, or to register for this event, visit Streamlined Microbiome Sequencing through Automation.

Stilla Technologies Solidifies Leadership in EMEA, Expands Footprint in APAC

Retrieved on: 
Tuesday, August 2, 2022
General Health, Health, Science, Other Science, Research, Food, Genomics, Industry, Twitter, DKSH, Caliper Life Sciences, CEO, Research, Infection, Multimedia, EMEA, Proteomics, Cancer, Technology, FUJIFILM, ITS, YouTube, LinkedIn, PCR, PerkinElmer, Management, Sergeant, Stilla, Eppendorf

Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.

Key Points: 
  • Stilla Technologies, the multiplex digital PCR company, announces the addition of Yvan Sergeant to serve in the capacity of Vice President/General Manager for the EMEA region.
  • Yvan held prior leadership positions at PerkinElmer, Caliper Life Sciences, and Trinean, and comes to Stilla from Quanterix where he served as VP/GM, Europe.
  • Along with the addition of Sergeant, Stilla Technologies also announces several new distribution partnerships in Asia.
  • With today's addition of six strategic partners in APAC, Stilla substantially increases its global market presence, and strengthens its ability to serve customers globally, notes Philippe Mourere, President and CEO of Stilla Technologies.

Takeda Becomes Founding Sponsor of LabCentral to Help Life Sciences Startups Accelerate New Medical Treatments

Retrieved on: 
Thursday, July 21, 2022
Selection Committee, Partnering, Main Street, Research, Marketing, Seed, Multimedia, Roche, LabCentral, Triumvirate Environmental, Eppendorf, Science, Patient, Heart, Kendall Square, 610, 700, Johnson & Johnson, Fine chemical, Pharmaceutical industry, Takeda

CAMBRIDGE, Mass., July 21, 2022 /PRNewswire/ -- LabCentral today announced that Takeda, a global biopharmaceutical leader headquartered in Japan with a global U.S. hub located in Massachusetts, will become a LabCentral Founding Sponsor. Takeda will provide funding over a period of three years to support LabCentral's biotech incubator located at 700 Main Street in the heart of Kendall Square in Cambridge, Mass. The Founding Sponsorship will provide strategic support for LabCentral's operations at the location, including its shared lab space and a robust range of programs designed to help its community of biotech startup residents accelerate their research and development.

Key Points: 
  • CAMBRIDGE, Mass., July 21, 2022 /PRNewswire/ -- LabCentral today announced that Takeda, a global biopharmaceutical leader headquartered in Japan with a global U.S. hub located in Massachusetts, will become a LabCentral Founding Sponsor.
  • LabCentral will allow a maximum of seven Founding Sponsorships for LabCentral 700, including up to four Sponsors from the pharmaceutical/biotech industry.
  • Takeda is joining existing Founding Sponsors Massachusetts Life Sciences Center (MLSC), Triumvirate Environmental, Johnson & Johnson Innovation, Roche and Eppendorf.
  • A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-sciences and biotech startups.

BioTools Innovator Announces Top 14 Life Sciences Companies Selected for 2022 Cohort

Retrieved on: 
Wednesday, July 6, 2022
Technology, Research, Medical Devices, Other Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Omni, Diagnosis, Half Moon Bay, California, LinkedIn, Hackensack Meridian Health, Mesa, Protein, NGS, Research Corporation, Growth, Biomedical Advanced Research and Development Authority, Danaher, Industry, Cell, Plasma, Lipid, Development, Eppendorf, Merck Millipore, Technology, Houston, RNA, Health, BARDA, Johnson & Johnson, Solution, PCR, Thermo Fisher Scientific, Twitter, Research, Pharmaceutical industry, Fine chemical, Medical imaging, Agilent Technologies

BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced that 14 companies have been selected to participate in its annual program.

Key Points: 
  • BioTools Innovator , the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health, announced that 14 companies have been selected to participate in its annual program.
  • Fourteen companies were then selected to participate in the BioTools Innovator Accelerator, which prominently features best-in-class life science startups from around the world.
  • BioTools Innovator matches industry leaders with innovative early stage and emerging growth biotechnology-focused companies for mentorship and support.
  • BioTools Innovator is powered by MedTech Innovator, the largest accelerator of medical device companies in the world and the premier nonprofit startup accelerator in the medical technology industry.

High Multiplex Proteomics Using a Proximity Extension Assay with an Automated Liquid Handling System, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 19, 2022
Protein, PEA, Workflow, Polymerase chain reaction, NGS, PCR, Food, Technology, Proteomics, Biology, Industry, Eppendorf

TORONTO, April 19, 2022 /PRNewswire-PRWeb/ -- Large-scale analysis of proteins is an integral part of the multi-omics approach in understanding human biology and identifying therapeutic targets. However, the full potential of proteomics has not been realized due to common limitations in technologies, including high sample consumption, low specificity, high inter- and intra-assay variations and narrow dynamic range. Here, the featured speakers discuss the combined benefits of a proximity extension assay with an automated liquid handling system.

Key Points: 
  • Attendees will learn how Olink Explore harnesses the power of next-generation sequencing (NGS) to enable high multiplex proteomics.
  • Here, the featured speakers discuss the combined benefits of a proximity extension assay with an automated liquid handling system.
  • Join this webinar to learn how the PEA technology automated on a liquid handling system can optimize and advance proteomics studies.
  • For more information, or to register for this event, visit High Multiplex Proteomics Using a Proximity Extension Assay with an Automated Liquid Handling System.

nRichDX and Eppendorf to Jointly Present at ESHG 2022 Meeting

Retrieved on: 
Thursday, April 14, 2022
CEO, DNA, CET, American Society of Human Genetics, Liquid biopsy, CO2, Automation, Conference, Urine, Plasma, European Society of Human Genetics, Eppendorf, Temperature, Laboratory, Industry, Nucleic acid thermodynamics, Method, Genetics, Fourth Industrial Revolution, Neoplasm, Bioreactor, Revolution, Workflow, Research, Medical device, Fine chemical

IRVINE, Calif., April 14, 2022 /PRNewswire/ -- nRichDX and Eppendorf will present data from the Revolution Semi-Automated Workflow™ powered by the epMotion® 5073 instrument at the upcoming European Society for Human Genetics (ESHG) 2022 Conference in Vienna, Austria on Saturday, June 11, 2022, from 10:00 am – 11:30 am CET.

Key Points: 
  • IRVINE, Calif., April 14, 2022 /PRNewswire/ -- nRichDX and Eppendorf will present data from the Revolution Semi-Automated Workflow powered by the epMotion 5073 instrument at the upcoming European Society for Human Genetics (ESHG) 2022 Conference in Vienna, Austria on Saturday, June 11, 2022, from 10:00 am 11:30 am CET.
  • The nRichDX Revolution Semi-Automated Workflow was developed in collaboration with Eppendorf and introduced in January 2021.
  • "We're excited to collaborate with our partner nRichDX at this year's ESHG conference," said Dr. Tim Schommartz, Global Marketing Manager Automated Liquid Handling at Eppendorf SE.
  • As digital solution, Eppendorf is developing new business models and transforming the Eppendorf portfolio to meet Industry 4.0 requirements.

LabCentral Releases 2021 Impact Report: Companies Raised $6.03 Billion in Funding and Launched 80 New Clinical Trials

Retrieved on: 
Thursday, April 7, 2022
Heart, Ignite, Economic development, Multimedia, Research, Venture capital financing, The Golden Ticket, Kendall Square, Industry, Ecosystem, LabCentral, Thermo Fisher Scientific, Eppendorf, Patient, Pharmaceutical industry

CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ --  LabCentral, a network of premier laboratory and co-working facilities for high-potential biotech start-ups, today announced its annual Impact Report detailing the influence of its 245 resident and 117 alumni companies on the local and national life sciences and biotech industry. The impact was measured in terms of clinical trials, investment, job creation as well as LabCentral's expanded facilities and programs from the past year. The 2021 Impact Report is available to download from LabCentral's website, in addition to reports from previous years.

Key Points: 
  • Key statistics from the LabCentral 2021 Impact Report include:
    Clinical Research Highlighting the success of its resident and alumni companies to quickly move from idea to research to clinical trials, LabCentral had more than 31 companies researching 24 unique indications with over 80 different technologies in clinical trials last year.
  • Since its founding in 2013, LabCentral companies have dosed 6,917 participants as part of clinical trials.
  • Funding LabCentral companies have raised a total of $16.9 billion in funding since 2013.
  • In 2021 alone, LabCentral resident and alumni companies secured $6.03 billion in funding from all sources.

nRichDX Launches Revolution Sample Prep™ Service

Retrieved on: 
Wednesday, March 30, 2022
Method, Nucleic acid thermodynamics, Neoplasm, Plasma, Research, NGS, TAT, CEO, Eppendorf, DdPCR, Fine chemical

IRVINE, Calif. , March 30, 2022 /PRNewswire/ -- nRichDX® Inc. announces the launch of its Revolution Sample Prep Service, for cfDNA and ctDNA extraction from researcher-provided plasma or urine samples of 1 mL to 20 mL.

Key Points: 
  • IRVINE, Calif., March 30, 2022 /PRNewswire/ -- nRichDX Inc. announces the launch of its Revolution Sample Prep Service, for cfDNA and ctDNA extraction from researcher-provided plasma or urine samples of 1 mL to 20 mL.
  • The service is for researchers who want to maximize the recovery and yield of cfDNA and ctDNA from plasma or urine samples, but may not yet need to purchase the Revolution Sample Prep System.
  • nRichDX continues to sell the Revolution Sample Prep System and kits and Semi-Automated Workflow powered by Eppendorf to its customers.
  • Revolution Sample Prep greatly enhances assay sensitivity and enables testing for earlier detection, monitoring, timely treatment, and optimal patient outcomes.